• Home
  • Opinion
  • Politics
  • World
  • Business
  • Science & Tech
Tuesday, January 31, 2023
No Result
View All Result
SUBSCRIBE
The Outlooker
27 °c
Delhi
  • Home
  • Opinion
  • Politics
  • World
  • Business
  • Science & Tech
  • Home
  • Opinion
  • Politics
  • World
  • Business
  • Science & Tech
No Result
View All Result
The Outlooker
No Result
View All Result
  • National
  • Politics
  • Opinion
  • Business
  • Science
  • World
  • Health
Home National

Drug Authority Says Reaction In Volunteer Not Linked To Covid Vaccine During Trial: Report

by The Outlooker Web Desk
December 2, 2020
in National
0
Bharat Biotech Starts Phase III Trials For COVAXIN
1.8k
SHARES
12.9k
VIEWS
Share on FacebookShare on Twitter

A volunteer in Chennai claimed to have suffered serious symptoms after vaccine shot. (Representational)

New Delhi:

A probe initiated by the Drugs Controller General of India (DCGI) into an alleged “serious adverse event” reportedly suffered by an Oxford COVID-19 vaccine trial participant in Chennai has found that it was not related to the shot administered to him, official sources said.

The DCGI arrived at the conclusion on Wednesday based on the recommendations of an independent expert committee which has also opined that compensation should not be paid to the volunteer, they said.

An independent expert panel comprising a doctor each from AIIMS, Safdarjung Hospital, The Post Graduate Institute of Medical Education and Research, located in Chandigarh, Lady Hardinge Medical College and Maulana Azad Medical College was constituted by the DCGI to look into the claim of a “serious adverse event” during the Serum Institute trial at a site in Chennai.

Last week, the 40-year-old man who was a volunteer in the third phase of the vaccine trial in Chennai claimed to have suffered serious neurological and psychological symptoms after taking the experimental shot. He has sued the SII along with others and sought compensation of Rs 5 crore, besides seeking a halt to the trial.

The SII, however, on Sunday rejected the charges as “malicious and misconceived” and said it will seek damages in excess of Rs 100 crore.

“The expert committee after due deliberation opined that the reported SAEs were not related to vaccine/clinical trial. Therefore, the committee recommends a compensation not to be paid to the subject or legal heir/ nominee of the subject,” the panel said in its recommendation.

Pune-based vaccine manufacturer SII had on Tuesday said that the vaccine is safe and immunogenic.

“We would want to assure everyone that the vaccine won’t be released for mass use unless it is proven immunogenic, and safe,” it said in a blog.

The Union Health Ministry officials on Tuesday said that the adverse event will not affect the timelines of vaccine-roll out in any manner, whatsoever.

They further stated that due processes about reporting the adverse event have been followed.

Newsbeep

ICMR Director General Dr Balram Bhargava had on Tuesday said adverse events do occur with drugs or vaccines or any other health intervention.

“If any adverse event warrants hospitalisation then it is called a serious adverse event. It is the role of the drug regulator, after collating all the data, to ascertain or refute whether there is a causal link between the event and the intervention.

“That causal link, whether it has to be ascertained or refuted, has to be done by the DCGI and all the papers in connection to it have been submitted to him accordingly for review,” Mr Bhargava said.

Stressing that it is done purely on a scientific basis and the assessment is done with very objectively-based criteria, Bhargava had said “initial causality assessment findings did not necessitate a stoppage of these trials”.

The Chennai-based business consultant was administered the shot at Chennai’s Sri Ramachandra Institute of Higher Education and Research (SRIHER), one of the trial sites on October 1.

A law firm on his behalf on November 21 sent a legal notice to Director General of ICMR, CEO, Serum Institute of India Private Limited, Pune, Drugs Controller General of India, Central Drugs Standard Control Organisation, CEO, Astra Zeneca UK, Professor Andrew Pollard, Chief Investigator of Oxford Vaccine Trial and Vice Chancellor of Sri Ramachandra Higher Education and Research.

The SII has partnered with British-Swedish biopharmaceutical giant AstraZeneca AstraZeneca for manufacturing the Oxford vaccine candidate for COVID-19.

(If you like reading The Outlooker, please consider subscribing to us below. Subscriptions are free for first 500 subscribers.)

The Outlooker Web Desk

The Outlooker Web Desk

Next Post
Nirav Modi’s Remand Extended In UK, Final Hearings In January 2021

Nirav Modi's Remand Extended In UK, Final Hearings In January 2021

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Padma Awardee Author Sudha Murty’s 4-Point Advice To Son-In-Law Rishi Sunak
National

Padma Awardee Author Sudha Murty’s 4-Point Advice To Son-In-Law Rishi Sunak

January 31, 2023
Nitish Kumar’s Sulking Aide Upendra Kushwaha Recalls A 1994 Challenge To Lalu Yadav
National

Nitish Kumar’s Sulking Aide Upendra Kushwaha Recalls A 1994 Challenge To Lalu Yadav

January 31, 2023
Virat Kohli, Anushka Sharma’s Spiritual Break In Rishikesh Ahead of Australia Test Series
National

Virat Kohli, Anushka Sharma’s Spiritual Break In Rishikesh Ahead of Australia Test Series

January 31, 2023
Seven Killed, Several Others Injured In Jeep-Trailer Truck Collision In Rajasthan
National

More Than 100 Students Fall Ill Due To Suspected Food Poisoning In Andhra Pradesh

January 30, 2023

Connect with us

No Result
View All Result

Archives

  • January 2023
  • December 2022
  • November 2022
  • October 2022
  • September 2022
  • August 2022
  • July 2022
  • June 2022
  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • January 2022
  • December 2021
  • November 2021
  • October 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
  • March 2021
  • February 2021
  • January 2021
  • December 2020
  • November 2020
  • October 2020
  • September 2020

Category

  • Artistic
  • Business
  • Crypto
  • Design
  • Entertainment
  • Fashion
  • featured
  • Food
  • Gaming
  • Health
  • Human
  • Lifestyle
  • Movie
  • Music
  • National
  • Opinion
  • Politics
  • Science
  • Spaces
  • Sports
  • Tech
  • Travel
  • Uncategorized
  • World

Recent Posts

  • Padma Awardee Author Sudha Murty’s 4-Point Advice To Son-In-Law Rishi Sunak
  • Nitish Kumar’s Sulking Aide Upendra Kushwaha Recalls A 1994 Challenge To Lalu Yadav
  • Virat Kohli, Anushka Sharma’s Spiritual Break In Rishikesh Ahead of Australia Test Series

About Us

The Outlooker

The Outlooker is your source of authentic, hand-picked news, stories, analysis from India & the World.

  • Terms Of Service
  • Privacy Policy
  • About us
  • Submit your story
  • Contact

© 2019-2021 The Outlooker. All rights reserved.

No Result
View All Result
  • Home
  • Politics
  • World
  • Business
  • Science
  • National
  • Entertainment
  • Gaming
  • Movie
  • Music
  • Sports
  • Fashion
  • Lifestyle
  • Travel
  • Tech
  • Health
  • Food

© 2019-2021 The Outlooker. All rights reserved.